Biogen acknowledged that in a statement, saying that Qalsody’s continued availability “may be contingent upon verification of clinical benefit in confirmatory trial(s).” VALOR missed its ...
Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. After a thorough review of the options trading surrounding ...
Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. Following our analysis of the options activities associated with ...
Some results have been hidden because they may be inaccessible to you